Guidance, NICE advice and quality standards in development | Guidance

Showing 131 to 140 of 404

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Eplontersen for treating hereditary transthyretin-related amyloidosis [ID6337]	Technology appraisal guidance	27 November 2024
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]	Technology appraisal guidance	TBC
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]	Technology appraisal guidance	26 February 2025
Evobrutinib for treating relapsing multiple sclerosis [ID6313]	Technology appraisal guidance	TBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920	Technology appraisal guidance	TBC
Exagamglogene autotemcel for treating sickle cell disease [ID4016]	Technology appraisal guidance	TBC
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests	Diagnostics guidance	TBC
Falls: assessment and prevention in older people and people 50 and over at higher risk (update)	NICE guideline	26 March 2025
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]	Technology appraisal guidance	TBC
Fertility problems: assessment and treatment	NICE guideline	6 August 2025